 |
|
Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jost B. Jonas, MD;
Peter Martus, PhD;
Robert F. Degenring, MD;
Ingrid Kreissig, MD;
Imren Akkoyun, MD
Arch Ophthalmol. 2005;123:1338-1343.
Objective To evaluate which factors influence maximum gain in best-corrected visual acuity after intravitreal injection of triamcinolone acetonide as treatment for diffuse diabetic macular edema.
Methods This prospective clinical interventional study included 53 eyes with diffuse diabetic macular edema receiving an intravitreal injection of about 20 mg of triamcinolone. The mean ± SD follow-up was 10.2 ± 7.6 months.
Results In a multiple linear regression analysis, maximum gain in best-corrected visual acuity after the intravitreal injection of triamcinolone was significantly (P < .001) and negatively correlated with an increased degree of macular ischemia and a higher preoperative visual acuity. Improvement in best-corrected visual acuity was significantly and positively correlated with increased degree of macular edema (P = .001). Change in best-corrected visual acuity after the intravitreal triamcinolone injection was statistically independent (P > .15) of age, sex, pseudophakia, and macula grid laser treatment before inclusion into the study. The results were comparable for gain in visual acuity at 6 months after the injection.
Conclusion Pronounced macular edema may have a positive impact, and marked macular ischemia and a high preoperative best-corrected visual acuity may have a negative impact, on an increase in best-corrected visual acuity after intravitreal triamcinolone injection in patients with diabetic macular edema.
Author Affiliations: Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Mannheim (Drs Jonas, Degenring, Kreissig, and Akkoyun); and Institute of Medical Informatics, Biostatistics, and Epidemiology, Benjamin Franklin School of Medicine, Free University of Berlin, Berlin (Dr Martus), Germany.
RELATED LETTERS
Intravitreal Triamcinolone in Diabetic Macular Edema
Sher Aslam, Nabeel Malik, and Nigel Davies
Arch Ophthalmol. 2006;124(10):1506-1507.
EXTRACT
| FULL TEXT
Intravitreal Triamcinolone in Diabetic Macular Edema—Reply
Jost B. Jonas, Peter Martus, Robert F. Degenring, Ingrid Kreissig, and Imren Akkoyun
Arch Ophthalmol. 2006;124(10):1507.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study
Brasil et al.
Br. J. Ophthalmol. 2007;91:761-765.
ABSTRACT
| FULL TEXT
Intravitreal Triamcinolone in Diabetic Macular Edema
Aslam et al.
Arch Ophthalmol 2006;124:1506-1507.
FULL TEXT
Intravitreal Triamcinolone in Diabetic Macular Edema--Reply
Jonas et al.
Arch Ophthalmol 2006;124:1507-1507.
FULL TEXT
|
